| 地黄饮子与阿仑膦酸钠治疗原发性骨质疏松症的病例对照研究 |
|
Hits: 1862
Download times: 1102
Received:September 26, 2018
|
| 作者 | Author | 单位 | Unit | E-Mail |
| 万俊明 |
WAN Jun-ming |
浙江省立同德医院骨科, 浙江 杭州 310002 |
Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310002, Zhejiang, China |
doctorwan@i.smu.edu.cn |
| 张建方 |
ZHANG Jian-fang |
浙江省立同德医院骨科, 浙江 杭州 310002 |
Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310002, Zhejiang, China |
|
| 黄恺 |
HUANG Kai |
浙江省立同德医院骨科, 浙江 杭州 310002 |
Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310002, Zhejiang, China |
|
| 张朋里 |
ZHANG Peng-li |
浙江省立同德医院骨科, 浙江 杭州 310002 |
Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310002, Zhejiang, China |
|
| 朱绍瑜 |
ZHU Shao-yu |
浙江省立同德医院骨科, 浙江 杭州 310002 |
Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310002, Zhejiang, China |
|
|
| 期刊信息：《中国骨伤》2019年32卷，第6期，第535-538页 |
| DOI：10.3969/j.issn.1003-0034.2019.06.010 |
| 基金项目:浙江省中医药科技计划项目（编号：2017ZB011）；浙江省医药卫生科技项目（编号：2016KYB051） |
|
目的：研究并对比分析服用中药汤剂地黄饮子与口服阿仑膦酸钠治疗原发性骨质疏松症的临床疗效差异。
方法：回顾自2016年1月至2017年12月骨质疏松专科门诊就诊的患者，筛选口服地黄饮子及阿仑膦酸钠规律用药满1年以上的原发性骨质疏松患者72例作为观察对象，将其分成两组，即试验组和对照组。试验组36例，男14例，女22例；年龄（63.97±3.70）岁；服用中药汤剂地黄饮子，每次1剂，早晚各1次，每周2次。对照组36例，男16例，女20例；年龄（63.36±3.07）岁；口服阿仑膦酸钠70 mg，每周1次。两组患者抗骨质疏松的基础治疗不变（每日口服碳酸钙D3片600 mg/d，以及骨化三醇胶丸0.5 μg/d）。采用双能X线骨密度仪检测两组患者治疗前和治疗1年后的股骨颈骨密度、腰椎骨密度，检测两组患者治疗前和治疗1年后的血清Ⅰ型胶原C末端肽（β-CTX）及血清硬骨素（SOST）含量并进行统计分析。
结果：抗骨质疏松治疗前两组患者的年龄、骨密度、SOST与β-CTX基线值比较，差异均无统计学意义（P>0.05）。两组患者在接受抗骨质疏松治疗1年后，股骨颈及腰椎骨密度均较治疗前增加，差异均有统计学意义（P<0.001）。血清β-CTX检测值均较治疗前明显降低，t值分别为52.002和50.071；血清SOST值均较治疗前增加，t值分别为-29.242和-30.807，差异均有统计学意义（P<0.001）。比较两组患者治疗后股骨颈和腰椎骨密度，P值分别为0.294和0.478，差异无统计学意义。两组患者接受治疗后的血清β-CTX值比较，P=0.908；两组患者治疗后的血清SOST值比较，P=0.888，差异无统计学意义。
结论：将传统中药地黄饮子用于治疗骨质疏松，研究发现其与阿仑膦酸钠均有较好的疗效，地黄饮子可作为治疗原发性骨质疏松症的中药选择。 |
| [关键词]:骨质疏松 植物药疗法 骨密度 病例对照研究 |
| |
| Comparison of the clinical effects between Dihuang Decoction(地黄饮子)and alendronate sodium in the treatment of primary osteoporosis |
|
Abstract:
Objective:To study and compare the clinical effects of Rehmannia Decoction and alendronate sodium for the treatment of primary osteoporosis.
Methods:From January 2016 to December 2017,72 patients with primary osteoporosis who took Dihuang Decoction(地黄饮子,DHD) orally and alendronate regularly for more than one year were randomly divided into 2 groups:experimental group and control group. The experimental group consisted of 14 males and 22 females,with an average age of(63.97±3.70) years old. The patients in the experimental group took Chinese medicine DHD,one dose each time,one time in the morning and one time in the evening,twice a week. The control group consisted of 16 males and 20 females with an average age of(63.36 ±3.07) years old. Patients in the control group were given alendronate 70 mg orally once a week. The basic treatment for osteoporosis remained unchanged in both groups(600 mg of calcium carbonate D3 and 0.5 μg of calcitriol capsules were taken daily). Bone mineral density (BMD) of femoral neck and lumbar vertebrae was measured by dual energy X-ray absorptiometry before and after treatment for one year. The levels of serum collagen typeⅠ C-terminal peptide (beta-CTX) and serum osteoclast (SOST) were measured before and after treatment for two groups.
Results:The age,bone mineral density,SOST and beta-CTX baseline values between the two groups before and after anti-osteoporosis treatment were compared. The difference was not statistically significant(P>0.05). Compared with the two groups,the BMD of femoral neck and lumbar vertebrae were increased after 1 year of anti-osteoporosis treatment. The differences were statistically significant (P<0.001). The value of serum beta-CTX was significantly lower than before. The t values were 52.002 and 50.071 respectively. The value of serum SOST was increased than that before treatment. The t values were -29.242 and -30.807 respectively. The differences were statistically significant (P<0.001). BMD of the femoral neck and lumbar spine was compared between the two groups after treatment. The P values were 0.294 and 0.478 respectively. The difference was not statistically significant (P>0.05). The serum beta-CTX values were compared between the two groups after treatment. The P value was 0.908. The serum SOST values were compared between the two groups after treatment. The P value was 0.888. The difference was not statistically significant (P>0.05).
Conclusion:In this study,traditional Chinese medicine DHD is used to treat osteoporosis. It is found that DHD and alendronate have a good effect. The DHD can be used as a choice of Chinese medicine in the treatment of primary osteoporosis. |
| KEYWORDS:Osteoporosis Phytotherapy Bone density Case-control studies |
| |
| 引用本文，请按以下格式著录参考文献： |
| 中文格式: | 万俊明,张建方,黄恺,张朋里,朱绍瑜.地黄饮子与阿仑膦酸钠治疗原发性骨质疏松症的病例对照研究[J].中国骨伤,2019,32(6):535~538 |
| 英文格式: | WAN Jun-ming,ZHANG Jian-fang,HUANG Kai,ZHANG Peng-li,ZHU Shao-yu.Comparison of the clinical effects between Dihuang Decoction(地黄饮子)and alendronate sodium in the treatment of primary osteoporosis[J].zhongguo gu shang / China J Orthop Trauma ,2019,32(6):535~538 |
|
| View Full Text View/Add Comment Download reader |
| Close |
|
|
|
